Evolocumab, a PCSK9 inhibitor, co-incubated with doxorubicin and trastuzumab reduces death of cardiomyocytes through reduction of MyD88-NLRP3-NF-kB-mTORC1
27 August 2021 (08:00 - 20:00)
Organised by:
Abstract
Slides
About the speaker

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)
187 More presentations in this session
Professor J. McMurray (Glasgow, GB)
Doctor S. Alampoondi Venkataramanan (Worcester, US)
Access the full session
The Event
ESC Congress 2021 - The Digital Experience
27 August 2021
08:00 CET
